Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
December 2025
Anti-CD38 monoclonal antibody CM313 for systemic lupus erythematosus: A randomized, double-blind, placebo-controlled Phase Ib/IIa trial
Signal Transduct Target Ther 2025;10:383 Doi: 10.1038/s41392-025-02487-2
Zhao et al. showed that CM313 was well tolerated in adult patients with SLE at doses of 2–16mg/kg and showed encouraging pharmacodynamic effects and preliminary efficacy at doses of 8 and 16 mg/kg QW. CM313 also produced dose-dependent and clinically meaningful improvements in key serological biomarkers of SLE.
September 2025
Efficacy and safety of upadacitinib as monotherapy or combined with elsubrutinib for the treatment of systemic lupus erythematosus: results through 104 weeks in a long-term extension study
RMD Open 2025;11:e005742 Doi:10.1136/rmdopen-2025-005742
In this long-term extension of the Phase 2 SLEek study, Merrill et al. report that through an additional 56-weeks of treatment, upadacitinib as monotherapy or combined with elsubrutinib demonstrated sustained or improved efficacy in multiple endpoints in patients with moderately to severely active SLE.
Keywords:
July 2024
Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for systemic lupus erythematosus: A Phase 2 randomized controlled trial
Arthritis Rheumatol 2024 DOI: 10.1002/art.42926 Epub ahead of print
Daily oral upadacitinib 30 mg and ABBV-599 high dose (elsubrutinib 60 mg QD + upadacitinib 30 mg) were effective in multiple outcome measures including disease activity, flares, time to first flare, and joint counts.